Scholarlink

<p><sup>18</sup>F-fluoromisonidazole (FMISO) is a positron emission tomography (PET) tracer used to detect tumor hypoxia. Although FMISO PET has been investigated in several experimental and early clinical studies, its utility for monitoring early treatment responses to immune checkpoint inhibitors (ICIs) remains unclear. Because hypoxia modulates the immunosuppressive tumor microenvironment, this pilot study evaluated whether changes in FMISO uptake before and after ICI initiation could serve as an exploratory predictor of treatment response in patients with advanced non-small cell lung cancer (NSCLC). Seventeen patients with advanced NSCLC who received nivolumab plus ipilimumab (Nivo-Ipi) were enrolled. FMISO PET was performed at baseline and at 9&#xa0;weeks after treatment initiation. Baseline tumor samples were assessed for CD4, CD8, FOXP3, and PD-L1 expression using standard immunohistochemical procedures. The objective response rate was 52.9%. The median baseline FMISO SUV<sub>max</sub> and SUV<sub>peak</sub> were 2.7 (range, 1.3–4.8) and 2.5 (range, 1.2–4.5), respectively. Patients who showed a ≥ 20% decrease in FMISO SUV after Nivo-Ipi demonstrated a 77.8% probability of achieving a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST). FMISO uptake was significantly correlated with 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose accumulation, tumor cell proliferation markers, prealbumin levels, tumor PD-L1, and stromal CD4 expression. When exploratory partial metabolic response (PMR) criteria of a ≥ 20% or ≥ 10% decrease in FMISO SUV were applied, progression-free survival differed significantly between PMR and non-PMR groups, whereas overall survival did not differ significantly. FMISO PET may serve as an exploratory tool for assessing early treatment response to ICIs in patients with advanced NSCLC. However, further studies are required to validate these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Kosuke Hashimoto,
  • Kyoichi Kaira,
  • Hisao Imai,
  • Atsuto Mouri,
  • Ayako Shiono,
  • Yu Miura,
  • Ou Yamaguchi,
  • Tomonori Kawasaki,
  • Hiroshi Kagamu,
  • Ichiei Kuji

摘要

18F-fluoromisonidazole (FMISO) is a positron emission tomography (PET) tracer used to detect tumor hypoxia. Although FMISO PET has been investigated in several experimental and early clinical studies, its utility for monitoring early treatment responses to immune checkpoint inhibitors (ICIs) remains unclear. Because hypoxia modulates the immunosuppressive tumor microenvironment, this pilot study evaluated whether changes in FMISO uptake before and after ICI initiation could serve as an exploratory predictor of treatment response in patients with advanced non-small cell lung cancer (NSCLC). Seventeen patients with advanced NSCLC who received nivolumab plus ipilimumab (Nivo-Ipi) were enrolled. FMISO PET was performed at baseline and at 9 weeks after treatment initiation. Baseline tumor samples were assessed for CD4, CD8, FOXP3, and PD-L1 expression using standard immunohistochemical procedures. The objective response rate was 52.9%. The median baseline FMISO SUVmax and SUVpeak were 2.7 (range, 1.3–4.8) and 2.5 (range, 1.2–4.5), respectively. Patients who showed a ≥ 20% decrease in FMISO SUV after Nivo-Ipi demonstrated a 77.8% probability of achieving a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST). FMISO uptake was significantly correlated with 2-deoxy-2-[18F] fluoro-D-glucose accumulation, tumor cell proliferation markers, prealbumin levels, tumor PD-L1, and stromal CD4 expression. When exploratory partial metabolic response (PMR) criteria of a ≥ 20% or ≥ 10% decrease in FMISO SUV were applied, progression-free survival differed significantly between PMR and non-PMR groups, whereas overall survival did not differ significantly. FMISO PET may serve as an exploratory tool for assessing early treatment response to ICIs in patients with advanced NSCLC. However, further studies are required to validate these findings.